Who are Irbesartan and Hydrochlorothiazide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Amlodipine/Losartan/Chlorthalidone, Amlodipine/Olmesartan, Amlodipine, Telmisartan, Amiloride Compound , Simvastatin, Nifedipine/Telmisartan, Ramipril + Irbesartan, Felodipine add Irbesartan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/irbesartan-and-hydrochlorothiazide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Irbesartan and Hydrochlorothiazide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Irbesartan and Hydrochlorothiazide (Irbesartan and Hydrochlorothiazide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thiazide Diuretic [EPC].

marketed Thiazide Diuretic [EPC] AT1 angiotensin II receptor Small molecule Live · refreshed every 30 min

Target snapshot

Irbesartan and Hydrochlorothiazide (Irbesartan and Hydrochlorothiazide) — Roxane Laboratories. Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by binding to the AT1 receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Irbesartan and Hydrochlorothiazide TARGET	Irbesartan and Hydrochlorothiazide	Roxane Laboratories	marketed	Thiazide Diuretic [EPC]	AT1 angiotensin II receptor
Amlodipine/Losartan/Chlorthalidone	Amlodipine/Losartan/Chlorthalidone	Hanmi Pharmaceutical Company Limited	marketed	Antihypertensive combination (calcium channel blocker + angiotensin II receptor blocker + thiazide diuretic)	L-type calcium channels, AT1 angiotensin II receptor, sodium-chloride cotransporter
Amlodipine/Olmesartan	Amlodipine/Olmesartan	Radboud University Medical Center	marketed	Calcium channel blocker / Angiotensin II receptor blocker combination	L-type calcium channels (amlodipine); AT1 angiotensin II receptor (olmesartan)
Amlodipine, Telmisartan, Amiloride Compound , Simvastatin	Amlodipine, Telmisartan, Amiloride Compound , Simvastatin	Chinese Academy of Medical Sciences, Fuwai Hospital	marketed	Antihypertensive combination (calcium channel blocker + angiotensin II receptor blocker + potassium-sparing diuretic + statin)	L-type calcium channels, AT1 angiotensin II receptor, epithelial sodium channels (ENaC), HMG-CoA reductase
Nifedipine/Telmisartan	Nifedipine/Telmisartan	Bayer	marketed	Calcium channel blocker + Angiotensin II receptor blocker combination	L-type calcium channels; AT1 angiotensin II receptor
Ramipril + Irbesartan	Ramipril + Irbesartan	Bristol-Myers Squibb	marketed	ACE inhibitor + Angiotensin II receptor blocker combination	ACE enzyme and AT1 angiotensin II receptor
Felodipine add Irbesartan	Felodipine add Irbesartan	LanZhou University	marketed	Calcium channel blocker + Angiotensin II receptor blocker combination	L-type voltage-gated calcium channels; AT1 angiotensin II receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thiazide Diuretic [EPC] class)

Cosette · 2 drugs in this class
Takeda · 2 drugs in this class
Daiichi Sankyo · 1 drug in this class
· 1 drug in this class
Generic (originally Merck) · 1 drug in this class
Generic (originally Merck/AstraZeneca) · 1 drug in this class
Roxane Laboratories · 1 drug in this class
Direct_Rx · 1 drug in this class
Aarxion Anda Hlding · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Irbesartan and Hydrochlorothiazide — Competitive Intelligence Brief. https://druglandscape.com/ci/irbesartan-and-hydrochlorothiazide. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab